NO335192B1 - Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse. - Google Patents

Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse. Download PDF

Info

Publication number
NO335192B1
NO335192B1 NO20045021A NO20045021A NO335192B1 NO 335192 B1 NO335192 B1 NO 335192B1 NO 20045021 A NO20045021 A NO 20045021A NO 20045021 A NO20045021 A NO 20045021A NO 335192 B1 NO335192 B1 NO 335192B1
Authority
NO
Norway
Prior art keywords
seq
abeta
peptide
amyloid
amino acid
Prior art date
Application number
NO20045021A
Other languages
English (en)
Norwegian (no)
Other versions
NO20045021L (no
Inventor
George-Hyslop Peter H St
Joanne Mclaurin
Original Assignee
Governing Council And The University Of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Governing Council And The University Of Toronto filed Critical Governing Council And The University Of Toronto
Publication of NO20045021L publication Critical patent/NO20045021L/no
Publication of NO335192B1 publication Critical patent/NO335192B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
NO20045021A 2002-04-19 2004-11-18 Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse. NO335192B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37391402P 2002-04-19 2002-04-19
PCT/CA2003/000502 WO2003089460A1 (en) 2002-04-19 2003-04-07 Immunological methods and compositions for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
NO20045021L NO20045021L (no) 2005-01-18
NO335192B1 true NO335192B1 (no) 2014-10-20

Family

ID=29251102

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20045021A NO335192B1 (no) 2002-04-19 2004-11-18 Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse.
NO20131483A NO20131483L (no) 2002-04-19 2013-11-07 Immunologiske fremgangsmåter og preparater for behandling av Alzheimers sykdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20131483A NO20131483L (no) 2002-04-19 2013-11-07 Immunologiske fremgangsmåter og preparater for behandling av Alzheimers sykdom

Country Status (17)

Country Link
US (5) US20030232758A1 (https=)
EP (2) EP1497321B1 (https=)
JP (3) JP4662719B2 (https=)
KR (1) KR100994748B1 (https=)
CN (1) CN100360555C (https=)
AT (1) ATE514707T1 (https=)
AU (1) AU2003218560B2 (https=)
CA (1) CA2481952C (https=)
ES (1) ES2368907T3 (https=)
IL (3) IL164643A0 (https=)
MX (1) MXPA04010255A (https=)
NO (2) NO335192B1 (https=)
NZ (1) NZ536064A (https=)
PL (1) PL209696B1 (https=)
SG (1) SG173214A1 (https=)
WO (1) WO2003089460A1 (https=)
ZA (1) ZA200408811B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
WO2003039467A2 (en) * 2001-11-02 2003-05-15 Diagenics International Corporation Monoclonal antibodies specific for beta-amyloid.
US20050106626A1 (en) * 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8193250B2 (en) 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
US20090123952A1 (en) * 2004-11-12 2009-05-14 Pfizer, Inc. Method of Measuring Amyloid-Beta Peptides
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
SG10201404801YA (en) 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
EP1992639A4 (en) * 2006-02-22 2009-08-26 Hayashibara Biochem Lab PEPTIDE VACCINE FOR INDUCING THE PRODUCTION OF AN ANTIAMYLOID PEPTIDANT BODY
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
WO2007126111A1 (ja) * 2006-04-28 2007-11-08 Kagoshima University アミロイドβ線維化阻害ペプチド
NZ574188A (en) 2006-07-14 2012-05-25 Ac Immune Sa Humanized antibody against amyloid beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008143708A2 (en) * 2006-12-07 2008-11-27 Mayo Foundation For Medical Education And Research Methods and materials related to anti-amyloid antibodies
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
RS53174B (sr) 2007-10-05 2014-06-30 Genentech Inc. Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
EP2365071B1 (en) * 2008-11-28 2016-04-06 Hokko Chemical Industry Co., Ltd. Transformed soybean plant which stores vaccine, and use thereof
CN101797493B (zh) * 2009-02-06 2014-05-21 上海抗体药物国家工程研究中心有限公司 一种在反应釜中制备亲和层析介质的方法
CN101486768B (zh) * 2009-02-25 2012-05-30 吉林大学 一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因
WO2010124028A2 (en) * 2009-04-21 2010-10-28 Vasylyev Sergiy V Light collection and illumination systems employing planar waveguide
JP5934645B2 (ja) 2009-09-11 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのヘテロ環式誘導体
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
DE102011057019A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen
MX366972B (es) * 2012-01-20 2019-08-01 Ananth Annapragada Metodos y composiciones para caracterizar imagenes medicas en forma objetiva.
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
EA201590459A1 (ru) * 2012-09-12 2015-11-30 Нейриммьюн Холдинг Аг Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
RU2689674C2 (ru) 2012-10-15 2019-05-28 Медиммьюн Лимитед Антитела к бета-амилоиду
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
PL3137094T3 (pl) 2014-04-29 2023-03-13 Advantage Therapeutics, Inc. Leczenie i profilaktyka choroby alzheimera (ad)
EP3166970B1 (en) 2014-07-10 2021-03-10 BioArctic AB Improved a-beta protofibril binding antibodies
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US10759837B2 (en) * 2015-11-09 2020-09-01 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
CN108699134A (zh) * 2015-12-10 2018-10-23 国家生物技术研究所公司 淀粉样β-蛋白前体抑制剂结构域的变体
BR112019009711A2 (pt) * 2016-11-25 2019-08-13 Genuv Inc método de indução de neuro-regeneração, método de proteção de neurônios contra perda ou dano neuronal, método de prevenção ou tratamento de doença neurodegenerativa devido à perda ou dano neuronal, e método de triagem de candidatos de fármaco para o tratamento de doenças neurodegenerativas
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
KR102710762B1 (ko) 2017-10-25 2024-09-25 얀센 파마슈티칼즈, 인코포레이티드 인산화 타우 펩티드의 조성물 및 이의 용도
CA3099946A1 (en) * 2018-05-18 2019-11-21 Universite Laval Use of nod2 agonist for the treatment, prophylaxis and/or delay of the onset of multiple sclerosis and alzheimer's disease
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
JP7505713B2 (ja) * 2019-02-22 2024-06-25 ロヨラ メリーマウント ユニバーシティ アミロイドペプチドバリアント
EA202192891A1 (ru) 2019-04-24 2022-02-04 Янссен Фармасьютикалз, Инк. Гетерологичное введение анти-тау вакцин
WO2021157634A1 (ja) * 2020-02-05 2021-08-12 大日本住友製薬株式会社 タウオパチーおよび認知症関連疾患の判定薬および判定方法
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
CN116234562A (zh) * 2020-05-15 2023-06-06 非营利性组织佛兰芒综合大学生物技术研究所 用于治疗病理性聚集的手段和方法
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN115786260B (zh) * 2022-12-26 2024-08-20 海南大学 Aβ42-hIAPP共寡聚化物诱导的AD脑类器官病理模型方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0671948T3 (da) 1992-06-25 1997-09-01 Smithkline Beecham Biolog Vaccinepræparat indeholdende adjuvanser
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
AU687805B2 (en) * 1993-04-27 1998-03-05 United Biomedical Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
WO1997007402A1 (en) 1995-08-17 1997-02-27 The Ontario Cancer Institute Protein fibril assembly assay
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
SI1292187T1 (sl) 2000-06-20 2006-10-31 Univ Toronto Transgenski zivalski model nevrodegenerativnih motenj
US6310810B1 (en) 2000-07-14 2001-10-30 Raj Kumar Jain High-speed sense amplifier
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
HK1072947A1 (en) 2005-09-16
PL373450A1 (en) 2005-08-22
SG173214A1 (en) 2011-08-29
AU2003218560A1 (en) 2003-11-03
CA2481952A1 (en) 2003-10-30
IL196532A (en) 2013-02-28
HK1158665A1 (en) 2012-07-20
IL196532A0 (en) 2009-09-22
JP5345920B2 (ja) 2013-11-20
JP2010065046A (ja) 2010-03-25
US20030232758A1 (en) 2003-12-18
ZA200408811B (en) 2005-07-27
KR100994748B1 (ko) 2010-11-17
ES2368907T3 (es) 2011-11-23
CN1646559A (zh) 2005-07-27
JP2006505502A (ja) 2006-02-16
US20140212481A1 (en) 2014-07-31
NO20045021L (no) 2005-01-18
EP2330113A1 (en) 2011-06-08
EP1497321B1 (en) 2011-06-29
AU2003218560B2 (en) 2009-09-03
IL164643A (en) 2011-11-30
EP1497321A1 (en) 2005-01-19
CN100360555C (zh) 2008-01-09
CA2481952C (en) 2013-10-29
JP2013075898A (ja) 2013-04-25
US20090041771A1 (en) 2009-02-12
US20120315321A1 (en) 2012-12-13
MXPA04010255A (es) 2008-03-04
ATE514707T1 (de) 2011-07-15
US20160297876A1 (en) 2016-10-13
IL164643A0 (en) 2005-12-18
EP2330113B1 (en) 2016-06-29
PL209696B1 (pl) 2011-10-31
JP4662719B2 (ja) 2011-03-30
NZ536064A (en) 2008-06-30
KR20040108747A (ko) 2004-12-24
NO20131483L (no) 2005-01-18
WO2003089460A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
NO335192B1 (no) Immunologiske peptider og peptidpreparater som induserer dannelse av antistoffer som spesifikt bindes til et amyloid-beta-peptid; deres anvendelse til fremstilling av et medikament for behandling av et individ som lider av Alzheimers sykdom, og en fremgangsmåte for bestemmelse av hvorvidt en forbindelse er en inhibitor av amyloide avleiringer og fibrilldannelse.
ES2714692T3 (es) Tratamiento de tauopatías
TWI353848B (en) Mimotope peptide,composition,and immunogenic compo
ES2962346T3 (es) Mimotopo
KR101517447B1 (ko) 루이 소체 질병을 치료하기 위한 알파-시누클레인 에피토프의 미모토프의 용도
MX2010013657A (es) Compuestos para tratar la amiloidosis.
MX2010013648A (es) Compuestos para tratar enfermedades.
KR20080097188A (ko) 항아밀로이드 면역성성분, 그 제조방법 및 용도
HK1072947B (en) Immunological methods and compositions for the treatment of alzheimer's disease
HK1158665B (en) Immunological methods and compositions for the treatment of alzheimer's disease
BRPI0908097B1 (pt) Peptídeo, formulação farmacêutica, e, uso de um composto

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees